Logo image of AONC

AMERICAN ONCOLOGY NETWORK IN (AONC) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AONC - US0287191029 - Common Stock

2.14 USD
+0.44 (+25.88%)
Last: 6/7/2024, 8:07:59 PM
1.75 USD
-0.39 (-18.22%)
After Hours: 6/7/2024, 8:07:59 PM
Fundamental Rating

1

AONC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of AONC have multiple concerns. AONC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year AONC has reported negative net income.
AONC had a positive operating cash flow in the past year.
AONC Yearly Net Income VS EBIT VS OCF VS FCFAONC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 10M -10M 20M -20M -30M

1.2 Ratios

AONC has a Return On Assets (-4.43%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -4.43%
ROE N/A
ROIC N/A
ROA(3y)2.93%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AONC Yearly ROA, ROE, ROICAONC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 5 -5

1.3 Margins

Looking at the Gross Margin, with a value of 8.08%, AONC is doing worse than 79.13% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for AONC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 8.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AONC Yearly Profit, Operating, Gross MarginsAONC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 2 4 6

3

2. Health

2.1 Basic Checks

AONC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AONC has less shares outstanding
Compared to 1 year ago, AONC has a worse debt to assets ratio.
AONC Yearly Shares OutstandingAONC Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M 40M
AONC Yearly Total Debt VS Total AssetsAONC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

AONC has an Altman-Z score of 1.88. This is not the best score and indicates that AONC is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.88, AONC is in line with its industry, outperforming 52.17% of the companies in the same industry.
The Debt to FCF ratio of AONC is 7.44, which is on the high side as it means it would take AONC, 7.44 years of fcf income to pay off all of its debts.
AONC's Debt to FCF ratio of 7.44 is fine compared to the rest of the industry. AONC outperforms 70.43% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 7.44
Altman-Z 1.88
ROIC/WACCN/A
WACC9.52%
AONC Yearly LT Debt VS Equity VS FCFAONC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 1.39 indicates that AONC should not have too much problems paying its short term obligations.
With a Current ratio value of 1.39, AONC perfoms like the industry average, outperforming 51.30% of the companies in the same industry.
AONC has a Quick Ratio of 1.20. This is a normal value and indicates that AONC is financially healthy and should not expect problems in meeting its short term obligations.
AONC's Quick ratio of 1.20 is in line compared to the rest of the industry. AONC outperforms 46.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.2
AONC Yearly Current Assets VS Current LiabilitesAONC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 50M 100M 150M 200M 250M

0

3. Growth

3.1 Past

The earnings per share for AONC have decreased strongly by -1431.78% in the last year.
EPS 1Y (TTM)-1431.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5307.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AONC Yearly Revenue VS EstimatesAONC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 200M 400M 600M 800M 1B

2

4. Valuation

4.1 Price/Earnings Ratio

AONC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AONC Price Earnings VS Forward Price EarningsAONC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of AONC indicates a rather cheap valuation: AONC is cheaper than 95.65% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.78
EV/EBITDA N/A
AONC Per share dataAONC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for AONC!.
Industry RankSector Rank
Dividend Yield N/A

AMERICAN ONCOLOGY NETWORK IN

NASDAQ:AONC (6/7/2024, 8:07:59 PM)

After market: 1.75 -0.39 (-18.22%)

2.14

+0.44 (+25.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.07%
Inst Owner Change0%
Ins Owners24.9%
Ins Owner Change0%
Market Cap78.69M
Revenue(TTM)1.02B
Net Income(TTM)-18.68M
AnalystsN/A
Price TargetN/A
Short Float %0.11%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.08
P/FCF 6.78
P/OCF 2.81
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.4
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.32
FCFY14.75%
OCF(TTM)0.76
OCFY35.61%
SpS27.87
BVpS-2.79
TBVpS-2.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.43%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 8.08%
FCFM 1.13%
ROA(3y)2.93%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover2.43
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 7.44
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.2
Altman-Z 1.88
F-Score4
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1431.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5307.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1151.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2622.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6191.09%
OCF growth 3YN/A
OCF growth 5YN/A

AMERICAN ONCOLOGY NETWORK IN / AONC FAQ

Can you provide the ChartMill fundamental rating for AMERICAN ONCOLOGY NETWORK IN?

ChartMill assigns a fundamental rating of 1 / 10 to AONC.


Can you provide the valuation status for AMERICAN ONCOLOGY NETWORK IN?

ChartMill assigns a valuation rating of 2 / 10 to AMERICAN ONCOLOGY NETWORK IN (AONC). This can be considered as Overvalued.


What is the profitability of AONC stock?

AMERICAN ONCOLOGY NETWORK IN (AONC) has a profitability rating of 1 / 10.